NewsBenzinga摩根士丹利维持对 Ultragenyx Pharmaceutical 的“与大盘持平”评级，将目标价上调至 22 美元 摩根士丹利维持对 Ultragenyx Pharmaceutical 的“与大盘持平”评级，将目标价上调至 22 美元 Benzinga 2026.11.04 18:17 (GMT+0) Open on Benzinga Other news US Court Denies Request for Temporary Restraining Order to Pause Single-Stock Perpetual Contracts Berlin Fintech Pliant Completes $80 Million Series C Round Led by Seaya Nova and Speedinvest Apex, Chainlink and Others Launch Modular Compliance Framework for Onchain Bonds Aligned With Swift Standards, Swift Joins ERC-3643 Association TD Cowen Maintains Buy on Aptiv, Lowers Price Target to $72 TD Cowen Maintains Buy on Apollo Global Management, Lowers Price Target to $136 TD Cowen Maintains Hold on American Well, Raises Price Target to $13
Apex, Chainlink and Others Launch Modular Compliance Framework for Onchain Bonds Aligned With Swift Standards, Swift Joins ERC-3643 Association
